Laurus Labs

May 25, 2023 06:18 AM IST

Hot Stocks | Here is why you should bet on Engineers India, LIC Housing Finance, Laurus Labs in short term

Engineers India stock has experienced a consolidation breakout on the daily chart, indicating a potential shift in its price trend.

Stock Of The Day: Laurus Labs

Laurus has corrected by about 50 percent from its 52-week high in April’22. This steep fall in the stock price has been in response to adverse supply-demand balance in the ARV industry along with degrowth in CDMO segment sales in the quarter gone by due to closure of a large purchase order. But what has changed for the company. Decoding the fundamentals.

Laurus Labs shares extend gains on USFDA approval for HIV drug

Laurus Labs closes 1.3 percent higher at Rs 311.60, with volumes of 45.5 lakh shares. The stock has gained 6 percent in two sessions

Laurus Labs: Is the worst priced in?

We expect FY24 to be the year of consolidation for top-line growth. Margins are expected to bottom out as operating leverage kicks in first for formulation capacity and later on for CDMO opportunity.

Hold Laurus Labs; target of Rs 338: Sharekhan

Sharekhan recommended Hold rating on Laurus Labs with a target price of Rs 338 in its research report dated April 28, 2023.

Buy Laurus Labs; target of Rs 340 : Motilal Oswal

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 340 in its research report dated April 27, 2023.

Laurus Labs Consolidated March 2023 Net Sales at Rs 1,380.90 crore, down 3.08% Y-o-Y

Laurus Labs Standalone March 2023 Net Sales at Rs 1,279.34 crore, down 7.14% Y-o-Y

Cash Market: Potential low risk opportunity in Laurus Labs

Laurus Labs has broken out of a long trendline and may look to create an intermediate leg up

Time for pharma industry to move from Make in India to Invent in India: Laurus Labs CEO

The government should look into incentivising disruptive research in the healthcare sector, says Satyanarayana Chava, the founder of the Hyderabad-based company that sells active pharmaceutical ingredients in over 55 countries.

Top 10 trading ideas for next 3-4 weeks as Nifty seems ready for a fresh climb

There is a possibility of Nifty may test psychological 18,000 mark followed by 18,200 in coming sessions, with strong support at 17,800-17,650 area, and also if the index surpasses the downward sloping resistance trendline adjoining highs of December 1, 2022 (record high) and January 24, 2023, then more upward move may be on cards, experts said.

Hold Laurus Labs; target of Rs 368: Sharekhan

Sharekhan recommended Hold rating on Laurus Labs with a target price of Rs 368 in its research report dated January 31, 2023.

Buy Laurus Labs; target of Rs 400: ICICI Direct

ICICI Direct is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 400 in its research report dated January 31, 2023.

Buy Laurus Labs; target of Rs 440: Motilal Oswal

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 440 in its research report dated January 30, 2023.

Laurus Labs shares tumble as Jefferies cuts target price

Choice Equity Broking, too, expects muted growth for the drugmaker because of a decline in margins due to a change in product mix and operating de-leverage

Laurus Labs: Is the worst over?

Material pick-up in earnings for Laurus Labs is contingent on the completion of capex projects

Laurus Labs Consolidated December 2022 Net Sales at Rs 1,544.82 crore, up 50.16% Y-o-Y

Laurus Labs Standalone December 2022 Net Sales at Rs 1,500.70 crore, up 60.92% Y-o-Y

Weekly Tactical Pick: Why this pharma company deserves a closer look

Steady growth visibility at Laurus Labs, backed by efforts towards diversification; valuation too is reasonable

Gainers & Losers: 10 stocks that moved the most on December 27

About 2,504 shares advanced, 889 shares declined, and 120 remained unchanged on December 27

Fire engulfs Laurus Pharma's Andhra unit; 4 workers dead, 1 critically injured

Laurus Pharma has launched an investigation for the cause of the fire. It estimates that the fire has caused no material impact on the operations of the company.

Laurus Labs slumps to 52-week low as Kotak Institutional Equities downgrades stock

Kotak has downgraded Laurus Labs to “sell” with a fair value of Rs 350/share, dragging the stock to intraday low of Rs 417

Laurus Labs to buy 26% stake in Ethan Energy at Rs 52.70 per share

The purchase will enable Laurus Labs to consume 100 percent of Ethan Energy's 10 MW solar plant

Buy Laurus Labs; target of Rs 600: Sharekhan

Sharekhan is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 600 in its research report dated October 25, 2022.

Buy Laurus Labs; target of Rs 610: Motilal Oswal

Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 610 in its research report dated October 22, 2022.